^
    9ms
    LX-101, A NOVEL, CLINICAL STAGE, PAYLOAD-BEARING TARGETED THERAPY DIRECTED TO THE INSULIN-LIKE GROWTH FACTOR RECEPTOR, HAS POTENT PRECLINICAL ANTI-TUMOR ACTIVITY AGAINST PEDIATRIC SARCOMAS (CTOS 2023)
    Objective: LX-101, a next-generation, targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R), consists of a proprietary IGF-1 variant coupled to a cytotoxic methotrexate (MTX) payload. These results demonstrate that LX-101 has potent preclinical anti-tumor activity against pediatric sarcoma cell lines with well-established ties to the IGF-1R pathway, including with different oncogenic gene fusions. These data further support the clinical development of LX-101 in IGF-1R-related pediatric cancers. A clinical trial is planned.
    Preclinical
    |
    EWSR1 (EWS RNA Binding Protein 1) • ERG (ETS Transcription Factor ERG) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • PAX3 (Paired Box 3)
    |
    PAX3-FOXO1 fusion
    |
    methotrexate • LX-101